# The Human Medicines (Amendments Relating to Naloxone and Transfers of Functions) Regulations 2024, Note: Explanatory note


(This note is not part of the Regulations)
These Regulations amend the Human Medicines Regulations 2012 (“the 2012 Regulations”), which govern the arrangements across the United Kingdom for the licensing, manufacture, wholesale dealing and sale or supply of medicines for human use.
A number of the amendments make provision about the supply of medicinal products containing naloxone or its salts, esters or stereoisomeric forms (“naloxone products”) which are prescription only medicines. Naloxone products are used in the diagnosis and treatment of cases of acute overdose or intoxication caused by natural or synthetic opioids.
Prior to these Regulations, limited provision had previously been made to allow people working for drug treatment services to benefit, when supplying naloxone hydrochloride, from an exemption from the ordinary restrictions in the 2012 Regulations on the supply of prescription only medicines. That exemption allowed people working for drug treatment services to supply naloxone hydrochloride without being authorised prescribers. New exemptions introduced by these Regulations also allow people working for the police, prison services, probation services and youth justice services – as well as a list of registered health care professionals – to supply the broader range of naloxone products, provided those individuals have undergone appropriate training. A new exemption is also created for the medical services of His Majesty’s forces.
A further new exemption is created for a new type of entity, referred to as local naloxone providers, whose workers will also benefit from the new exemptions. These local naloxone providers will be part of networks, run on behalf of central government and the devolved administrations by entities that agree to act as naloxone supply network co-ordinators. The local naloxone arrangements that are to govern the local supply are required to cover a list of issues that includes appropriate training, the storage and handling of naloxone products and record keeping. Specific provision has also been made for the transfer of information to specified national bodies.
Provision has also been made to allow specified national bodies to set national standards for training in the storage and supply of naloxone products nationally.
Supplies of naloxone by all the individuals coming within these exemptions will need to be for a specified purpose. Prior to these Regulations, under the exemption that was just for drug treatment services, the permitted purpose for supply was limited to the actual saving of life in an emergency, but under the new arrangements, suppliers will be able to supply “take home” naloxone products, and to supply naloxone products to be carried about, for example by police officers, in case they are needed (regulations 3 and 7).
The earlier more limited exemption for drug treatment services has been subsumed into the new exemption, allowing for its revocation (regulations 9(b) and 11). The list of products that may be parenterally administered in an emergency has been updated so that it now refers to naloxone products rather than simply naloxone hydrochloride (regulation 12).
An adjustment has been made to the powers of medicines manufacturers and wholesalers to allow them to supply naloxone products to providers that are part of the new arrangements (regulation 8).
Public Health England (PHE), which has been dissolved, was an executive agency of the Department of Health and Social Care (DHSC) – and many of its functions have been transferred to the United Kingdom Health Security Agency (UKHSA), which is also an executive agency of DHSC. PHE’s functions that were specified in the 2012 Regulations, and those of its chief executive, which relate predominantly to the supply of prescription only medicines under patient group directions, have been transferred to the UKHSA and its chief executive (regulations 4(b) and (c), 5, 6, 9(a) and (c), 10 and 13).
Similarly, the functions of the Regional Health and Social Care Board in Northern Ireland which related to patient group directions have been transferred to the Department of Health in Northern Ireland. Regulation 4(a) of these Regulations amends a definition of “health authority” to make it clear that this transfer has taken place, although the transfer itself happened by virtue of a transitional provision in paragraph 1 of Part 2 of Schedule 4 to the Health and Social Care Act (Northern Ireland) 2022 (c. 3).
A Regulatory Triage Assessment of the effect of this instrument was undertaken and it was deemed that a full impact assessment would not be proportionate. These Regulations are not expected to have a significant impact on the public and voluntary sectors, and only a limited impact on the private sector, below the threshold for undertaking a full impact assessment.

---
Source: https://www.legislation.gov.uk/ukdsi/2024/9780348262797/note (the official version)
Page: https://openlegislation.uk/draft-human-medicines-amendments-relating-to-naloxone-and-transfers-of-functions-regulations-2024/note
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

